Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 2/20 | 0.44 |
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
| ▸ | CETP | P11597 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL273935 | 0.89 | CTSK (0.50) | CTSKCES2CES1RECQLALDH1A1 | |
| Butyric Acid SCHEMBL14763643 | 0.85 | CTSK (0.47) | CTSKRECQLALDH1A1 | |
| SCHEMBL27870286 | 0.83 | CES2 (0.47) | EPHX2MEN1KMT2ACES2CES1 | |
| SCHEMBL872678 | 0.82 | KCNH2 (0.51) | CTSKRECQLALDH1A1 | |
| SCHEMBL27484992 | 0.80 | CTSK (0.50) | CTSKRECQLALDH1A1 | |
| SCHEMBL3833989 | 0.79 | TSHR (0.51) | CTSKKMT2ACES2CES1RECQL | |
| SCHEMBL27632022 | 0.78 | KMT2A (0.43) | CTSKEPHX2MEN1KMT2AMMP1 | |
| SCHEMBL5556046 | 0.78 | CYP3A4 (0.49) | CTSKRECQLALDH1A1 | |
| SCHEMBL10710422 | 0.77 | EPHX2 (0.46) | CTSKEPHX2MEN1KMT2AMMP1 | |
| SCHEMBL16685247 | 0.77 | ALDH1A1 (0.43) | EPHX2MEN1KMT2ACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277012-A1 | DUPLICATE BEVERAGE | WANG JIE (US) | 2024-08-22 | — | — | US | disclosed |
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| EP-3368542-B1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11357246-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | CTSK 3504/4885EPHX2 3756/4885MEN1 2644/4885 |
| US-11357246-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | CTSK 3504/4885EPHX2 3756/4885MEN1 2644/4885 |
| US-11758933-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | CTSK 3504/4885EPHX2 3756/4885MEN1 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.